Non-Opioid Therapy NYX-2925 Blocks Pain Hypersensitivity in Fibromyalgia Patients, Phase 2 Trial Shows

Non-Opioid Therapy NYX-2925 Blocks Pain Hypersensitivity in Fibromyalgia Patients, Phase 2 Trial Shows
Treatment with the new, non-opioid small molecule NYX-2925 can block hypersensitivity to pain in patients with fibromyalgia, results from an exploratory clinical study show. The oral compound, being developed by Aptinyx, also induced statistically significant changes on neuroimaging biomarkers, fatigue, and overall function. These top-line data from NYX-2925’s Phase 2 trial will be presented at the American College of Rheumatology (ACR) 2019 Annual Meeting, to be held Nov. 8-13 in Atlanta. The electronic poster is titled “NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia.” “The opportunity to showcase these clinical data in a late-breaking presentation demonstrates their scientific importance in a field in dire need of new therapeutic options,” Norbert Riedel, PhD, president and CEO of Aptinyx, said in a press release. “Taken together, the imaging data and the clinical outcomes from this study are highly supportive of the continued development of NYX-2925 in chronic centralized pain conditions.” NYX-2925 is designed to modulate the response of NMDA receptors, which are critical mediators of nerve cells’ communication and transmission of pain signals in the brain and spinal cord. The safety and efficacy of this new therapy was evaluated in a randomized, placebo-controlled Phase 2 trial (NCT03249103). That study was conducted in collaboration with the Chronic Pain and Fatigue Research Center at the University of Michigan Medical School and the Women's Health Research Program at University of Cincinnati College of Medicine. The trial enrolled 22 right-handed women diagnosed with fibromyalgia who received once-daily doses of placebo for two weeks, followed by
Subscribe or to access all post and page content.